AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Q1 2016 Earnings Presentation

30 slides from AMAG Pharmaceuticals's earnings presentation, May 3, 2016

  1. Slide 1: Forward-looking statements

    This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including among others, statements regarding the impact of inves

  2. Slide 2: Q1-2016 Earnings Call Agenda

    Q1-2016 Earnings Call Agenda Q1-2016 Highlights 1 5 2016 Key Priorities and Closing Remarks 5 Q&A 6 2 Commercial Updates 4 Q1-2016 Financial Update 3 Pipeline Updates

  3. Slide 3: Q1-2016 Highlights

    Q1-2016 Highlights Product Highlights Makena sales grew 17% percent over Q1-2015 Received FDA approval of single-dose, preservative-free formulation of Makena Commercial launch underway with positive early leading indicators Signed agreement with a leading provider of home nursing services to exclus

  4. Slide 4: Q1-2016 Financial Highlights

    Q1-2016 Financial Highlights Non-GAAP Product Revenue1 ($ MM) +52% 1See slides 24-25 for reconciliations of GAAP to non-GAAP financial information. Balance Sheet $480 MM ending cash & investments balance; increased by $13.9 MM $7.6 MM utilized to purchase 320,000 shares of common stock and $4.4 MM u

  5. Slide 5: Commercial Update: Maternal Health

    Commercial Update: Maternal Health

  6. Slide 6: Makena: Positioned in Large Market, Growing Share

    MATERNAL HEALTH: MAKENA Positioned in Large Market, Growing Share Makena Sales up 17% over Q1-2015 1 Company estimates Makena market share based on distributor dispensing data and all other market share based on physician market research data conducted by AMAG. 2 Based on 140,000 patients, >16 injec

  7. Slide 7: Single-Dose Makena Leading to New Growth

    MATERNAL HEALTH: MAKENA Single-Dose Makena Leading to New Growth Single-dose Vial of Makena Preservative free Convenient for healthcare providers 4-pack aligns with insurers’ policies FDA approval Commercial launch ü ü Early Launch Metrics Makena Care Connection Referrals1 1 Makena Care Connection (

  8. Slide 8: Makena Growth Drivers in 2016 and Beyond

    New partnership with a leading provider of home nursing services At-home administration by a healthcare professional Continued share gains from compounders Preservative-free launch could expand compounder pharmacy conversion to become Makena distributor Continue to pull through formulary expansions

  9. Slide 9: CBR: Market Leader, Long Growth Runway

    MATERNAL HEALTH: CBR CBR: Market Leader, Long Growth Runway 9 Attractive business model One-time upfront collection fee Ongoing annual storage fee (high margin) High loyalty; <1% annual attrition Market for Stored Cord Blood CBR Non-GAAP Pro Forma Revenue1 ($ MM) 2.5% bank publicly 2.5% bank private

  10. Slide 10: CBR Growth Drivers in 2016 and Beyond

    Growing birth rate in the U.S. Market expansion opportunities Only 5% of families store cord blood Expand market offerings Optimize revenue through strategic pricing Increase share Expanded sales force from 47 to 104 reps in Q3-2015 Portfolio of products allows for broader relationships with target

  11. Slide 11: Commercial Update: Hematology/Oncology & Hospital

    Commercial Update: Hematology/Oncology & Hospital

  12. Slide 12: Feraheme: Record Breaking Quarterly Sales

    HEMATOLOGY / ONCOLOGY BUSINESS: FERAHEME Record Breaking Quarterly Sales Strong commercial team & Differentiated product +13% Growth from volume +7% and price +6% Patent protection through 20231 6 Orange Book listed patents 5 expire in 2020 1 expires in 2023 Growing IV iron market2 Growth opportunit

  13. Slide 13: Feraheme Growth Drivers in 2016 and Beyond

    HEMATOLOGY / ONCOLOGY BUSINESS: FERAHEME Growth Drivers in 2016 and Beyond Grow share in hospital segment Maximize opportunity in Hem/Onc segment Optimize net revenue per gram Growth Drivers Next 2-3 Years Label expansion1 – All adult IDA patients who have failed or cannot tolerate oral iron treatme

  14. Slide 14: Pipeline Update

    14 Pipeline Update Copyright © 2016 AMAG Pharmaceuticals. All Rights Reserved.

  15. Slide 15: Next Generation Development Programs

    Next Generation Development Programs Easier administration for physicians/nurses Potential for less painful injections Working with proven device partner, Antares, with issued patents to 2026 Additional patent applications pending Eligible for orphan exclusivity on drug device combination sNDA estim

  16. Slide 16: Next Generation Development Programs

    & 2mag Next Generation Development Programs Makena Subcutaneous Auto-injector Feraheme Phase 3 IDA Trial * Easier administration for physicians/nurses > Seeking broad IDA indication ~ Doubles the addressable market for Feraheme * Potential for less painful injections * Working with proven device par

  17. Slide 17: Q1-2016 Financial Highlights

    Q1-2016 Financial Highlights Adjusted EBITDA and non-gaap eps1 ($ in millions, except per share data) Q1-2016 Q1-2015 Makena product sales $65.0 $55.5 Feraheme/ MuGard product sales $24.5 $21.9 Non-GAAP CBR service revenues $28.1 -- Total non-GAAP Product Revenues $117.6 $77.4 Non-GAAP adjusted EBIT

  18. Slide 18: Q1-2016 GAAP to Non-GAAP Comparison

    Q1-2016 Financial Results GAAP to NON-GAAP Comparison1 1 See slides 24-25 for a reconciliations of GAAP to non-GAAP financial information. 2 See slide 27 for share reconciliation. ($ in millions, except per share data) Q1-2016 (GAAP) Adjustments Q1-2016 (Non-GAAP) Total revenues $109.3 $8.6 $117.9 C

  19. Slide 19: Confirming 2016 Financial Guidance

    Confirming 2016 Financial Guidance ($ MM) 2016 Guidance1 % Increase over 2015 (midpoint of guidance) Makena sales $310 - $340 +29% Feraheme and MuGard sales $95 - $105 +11% Cord Blood Registry revenue $115 - $1253 +1%2 Total non-GAAP product revenue1 $520 - $570 +42% Non-GAAP adjusted EBITDA1 $255 -

  20. Slide 20: Confirming 2016 Financial Guidance

    &amag Confirming 2016 Financial Guidance ($ MM) 2016 Guidance? % Increase over 2015 (midpoint of guidance) Makena sales $310 - $340 +29% Feraheme and MuGard sales $95 - $105 +11% Cord Blood Registry revenue $115 - $125? +1%? Total non-GAAP product revenue? $520 - $570 +42% Non-GAAP adjusted EBITDA?

  21. Slide 21: Executing on 2016 Key Priorities

    Executing on 2016 Key Priorities Financial and Commercial Drive significant net product sales growth +40% versus prior year Commercialize single-dose, preservative-free formulation of Makena Non-GAAP adjusted EBITDA of >$255 MM Initiate share repurchase program Product Development Conduct Makena bio

  22. Slide 22: AMAG Pharmaceuticals Q1-2016 Financial Results

    AMAG Pharmaceuticals Q1-2016 Financial Results May 3, 2016

  23. Slide 23: Appendix

    AMAG Pharmaceuticals Appendix Q1-2016 Financial Results May 3, 2016

  24. Slide 24: GAAP to non-GAAP Financials for Q1 2016 (cont.)

    GAAP to non-GAAP Financials for the First Quarter Ended March 31, 2016 (cont.) Footnotes 4 Adding back period write-down of deferred revenue from purchase accounting. 5 Eliminate non-cash revenue related to recognition of previously deferred revenue on Takeda agreement. 6 Eliminate the following: (i

  25. Slide 25: 2016 Financial Guidance Reconciliation

    2016 Financial Guidance Reconciliation ($ MM) 2016 Guidance GAAP net income $11 - $41 CBR deferred revenue purchase accounting adjustments $17 Depreciation & amortization $90 Interest expense, net $72 Provision for income taxes $20 EBITDA $210 - $240 Non-cash inventory step-up $5 Stock-based compens

  26. Slide 26: Share Reconciliation

    Share Reconciliation 1 Employee equity incentive awards, Convertible notes and Warrants would be anti-dilutive in this period utilizing the “if-converted” method, which adjusts net income for the after-tax interest expense applicable to the convertible notes. 2 Reflects the Non-GAAP dilutive impact

  27. Slide 27: Capitalization as of March 31, 2016

    ($ MM) Cash, cash equivalents and investments $480 Convertible senior notes (2.5%) $200 Term loan facility (4.75%) 341 2023 senior notes (7.875%) 500 Total debt (principal amount outstanding) $1,041 Capitalization As of March 31, 2016 ($ MM) Shares outstanding (millions) 34.6 Net operating loss bala

  28. Slide 28: CBR Non-GAAP Revenue Adjustment

    CBR Non-GAAP Revenue Adjustment Purchase accounting future impact Deferred revenue balance on August 17, 2015 Addback to calculate non-GAAP revenue to be reported in future periods ($ MM) Purchase accounting rules require write-down of closing date deferred revenue on balance sheet at acquisition da

  29. Slide 29: AMAG Pharmaceuticals Q1-2016 Financial Results

    AMAG Pharmaceuticals Q1-2016 Financial Results May 3, 2016

  30. Slide 30: AMAG Pharmaceuticals

    r Pharmaceuticals» > ‘A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS’ LIVES ‘Copyright © 2016 AMAG Pharr tials ne. Al Rights Reserved.

Amag Pharmaceuticals — Q1 2016 Earnings Presentation on 6ix